Project Grant R44CA221624

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $676,006 to The Regents of the University of California, San Francisco to develop and test molecular imaging strategies to identify mechanisms of resistance to immunotherapies for cancer. The key products and services to be delivered include: Using PET imaging to measure levels of granzyme B, which contributes to immunotherapy response, and neutrophil levels, which...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,453,091 to The Trustees of the University of Pennsylvania for the development of an imaging-enabled, adaptable CAR T cell (IMAC) platform. The goal is to create a theranostic IMAC method that allows for the monitoring and quantitative control of CAR T cell activity against solid tumors, specifically targeting folate receptor-expressing ovarian cancer cells and...

This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of a novel circulating tumor DNA (ctDNA) assay technology for monitoring the efficacy of immunotherapy in patients with non-small cell lung cancer. The $990,771 award, effective from September 2024 to August 2026, aims to build clinical data to support the utility of this epigenetic-based ctDNA assay, which can broadly detect...

This $1,625,000 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development and validation of a radiomics-based, multi-modal predictive model for assessing response to PD-1/PD-L1 immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC). The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study; 2) Evaluate the performance...

This $204,295 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to integrate advanced molecular imaging techniques, including Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI), to quantify HER2 expression and vascular perfusion in HER2-positive breast-to-brain metastases. The key objectives are to: 1) Quantify HER2 expression and vasculature to assess the bioavailability of the HER2-targeted therapy...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...

This $399,829 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research by The Washington University in St. Louis to validate an S1PR1-targeted PET imaging approach that can quantitatively measure early response to antibody-drug conjugate (ADC) therapies in gastric cancer models. The research aims to correlate tumor S1PR1 levels, HER2 availability, and genetic alterations with gastric tumor response to ADCs. Through...

The National Cancer Institute (NCI) has awarded a $678,515 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The University of Texas MD Anderson Cancer Center. The grant's objective is to evaluate an innovative 18F-FSPG Positron Emission Tomography (PET) imaging approach to predict early response and recurrence following Yttrium-90 (Y90) radioembolization therapy in patients with hepatocellular carcinoma (liver cancer). The project will also determine if...

This $497,870 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Cincinnati. The grant aims to develop novel nuclear imaging probes using bacterial metallophores to non-invasively monitor and track genome-edited immune cells, such as CAR-T cells, after adoptive cell transfers. The key products and services to be delivered under this grant include: 1) developing and evaluating bacterial...

This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...